Nyrada Inc
Company Profile
Business description
Nyrada Inc is a preclinical-stage, drug discovery, and development company, specializing in novel small-molecule drugs to treat cardiovascular and neurological diseases. It operates in one segment: research and development of drugs focusing on small molecules with potential therapeutic benefit in areas of medical needs. The company's two programs center on cholesterol-lowering and brain injury, each targeting market sectors of notable size and unmet clinical needs. The programs are focused on developing an oral, small molecule cholesterol-lowering drug, and a drug to treat secondary brain damage following a stroke or traumatic brain injury.
Contact
180 George Street, Sydney Place
Level 22/23, Salesforce Tower
SydneyNSW2000
AUST: +61 294983390
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
Stocks News & Analysis
stocks
Chart of the Week: AI proving a threat to company moats
stocks
ASX coal miners will benefit from higher prices
stocks
Nvidia earnings: Another stellar quarter with no signs of a slowdown
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,699.70 | 12.10 | -0.14% |
| CAC 40 | 7,969.88 | 4.61 | -0.06% |
| DAX 40 | 23,502.25 | 228.67 | -0.96% |
| Dow JONES (US) | 46,199.62 | 793.64 | -1.69% |
| FTSE 100 | 10,305.29 | 98.31 | -0.94% |
| HKSE | 25,593.03 | 432.39 | -1.66% |
| NASDAQ | 22,164.37 | 315.16 | -1.40% |
| Nikkei 225 | 53,655.75 | 1,583.65 | -2.87% |
| NZX 50 Index | 13,070.50 | 111.73 | -0.85% |
| S&P 500 | 6,626.82 | 89.27 | -1.33% |
| S&P/ASX 200 | 8,507.00 | 1.60 | 0.02% |
| SSE Composite Index | 4,024.23 | 38.75 | -0.95% |